Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001310623 | SCV001500497 | uncertain significance | not provided | 2020-10-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001310623 | SCV002277711 | likely benign | not provided | 2023-07-07 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV001310623 | SCV003827168 | uncertain significance | not provided | 2021-05-13 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004968004 | SCV005511473 | uncertain significance | Inborn genetic diseases | 2024-11-27 | criteria provided, single submitter | clinical testing | The c.4430G>A (p.R1477H) alteration is located in exon 13 (coding exon 13) of the TECTA gene. This alteration results from a G to A substitution at nucleotide position 4430, causing the arginine (R) at amino acid position 1477 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |